98.75 USD
▲-1.60+0.30%
2026-08-03
市值
$21.40B
市盈率
—
EPS
-5.70
股息率
—
52 周区间
90.39 – 212.75
成交量
4.29M
Beta
0.78
目标价
196.18
52W 低 90.3952W 高 212.75
价格走势
公司简介
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ...